Overview
Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion (CRVO). However, there is little information on whether there are any predictive factors of treatment outcome after this treatment. We plan to perform comprehensive functional and imaging tests to determine significant predictive factors.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mie UniversityTreatments:
Ranibizumab
Criteria
Inclusion Criteria:- Macular edema associated with central retinal vein occlusion
- Best corrected visual acuity < 20/30
- Central macular thickness > 300
- Period from symptom onset to treatment < 12 months
Exclusion Criteria:
- Any past history of treatment for macular edema (e.g. anti-VEGF injection, steroid,
vitrectomy)